Navigation Links
LipiGesic M stands alone among over-the-counter migraine medications based on recently released American Headache Society recommendations
Date:11/29/2013

SCHOFIELD, Wis., Nov. 29, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCBB:PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that its product, LipiGesic® M does not contain caffeine, acetaminophen, or aspirin. It is the only clinically tested, non-prescription migraine medication available on retail shelves today that has shown no evidence of rebound or "medication overuse headache" as a reported side effect.

In the article entitled, "Choosing Wisely in Headache Medicine: The American Headache Society's List of Five Things Physicians and Patients Should Question," the authors warn physicians not to "recommend prolonged or frequent use of over-the-counter (OTC) pain medications for headache." The American Headache Society (AHS) article recommended that OTC headache pain relievers should not be used more than twice a week to avoid the incidence of "medication overuse headache," especially when the medications contain caffeine. The article goes on to cite the dangers of liver damage caused by the overuse of acetaminophen and gastrointestinal bleeding caused by overuse of nonsteroidal anti-inflammatory drugs.

"Having a product like LipiGesic M that does not produce 'medication overuse headache' is important in light of the latest report published by the AHS," said Russell Mitchell, CEO of PuraMed BioScience. "There have been no reported occurrences of LipiGesic M causing a rebound headache no matter how frequently a person uses it. LipiGesic M's patented formulation of feverfew and ginger also has not been shown to cause liver damage, stomach bleeding, or other adverse side effects."

When writing the "Choosing Wisely in Headache Medicine: ..." article published in the November/December 2013 issue of Headache, the authors asked AHS members to suggest tests, procedures, or treatments in headache medicine that were commonly overused or misused. The five suggestions selected "were associated with poor patient outcomes, low value care or documented overuse or misuse," the study said.

"LipiGesic M is not like the pain relievers that are cited in the study," said Mitchell. "Based on the results of our clinical trial, LipiGesic M performs more like a prescription migraine medication than an OTC migraine formulation, but without the unwanted side effects associated with either product category."

This fact was also stated in Advances in Drug Development for Acute Migraine, an article published in Drugs medical journal in December 2012. Speaking of LipiGesic M, the authors, including headache expert Dr. Roger Cady, said, "Advantages of this product include lower cost, OTC availability, and it is not likely to produce medication overuse headache. It is an excellent first-line therapy for very early intervention, as it is compatible with all other acute treatment options."

The Cleveland Clinic website also lists many medications that can cause rebound headache. The list includes: "aspirin, sinus relief medications, acetaminophen, nonsteroidal anti-inflammatory medications (NSAIDs), sedatives for sleep, codeine and prescription narcotics, and over-the-counter combination headache remedies containing caffeine (such as Anacin®, Excedrin®, Bayer Select®, and others)." http://my.clevelandclinic.org/disorders/Headaches/hic_Rebound_Headaches.aspx

"Recently there have been an increased number of Food and Drug Administration safety warnings associated with acetaminophen and other OTC pain medications," said Mitchell. "People forget that many OTC medications were only available as prescriptions when they were first introduced. That's why it is personally gratifying to offer a highly effective treatment for acute migraine that does not cause the harmful side effects mentioned by the report."

Currently, PuraMed BioScience has 68,702,155 shares outstanding.

About PuraMed BioScience, Inc.:
PuraMed BioScience has completed a double blind placebo clinical trial for its leading product, LipiGesic® M, a sublingual acute treatment for the relief from migraine headaches, which was published in the top-tier medical journal, Headache. http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4610.2011.01910.x/abstract. LipiGesic® M has national distribution and is available nationwide in some of the largest chain drug stores in the United States.

Forward-Looking Statements:
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Contact:
PuraMed BioScience, Inc.
Patricia McMurtrie
715-571-4910
patricia@PuramedBioScience.com
www.PuramedBioScience.com


'/>"/>
SOURCE PuraMed BioScience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PuraMed BioScience Sponsors Miles for Migraine Race with LipiGesic M
2. PuraMed BioScience Invited to Discuss LipiGesic M on Armed Forces Network
3. Leading Cardiologist Stands By Use of Dietary Supplement Niacin in the Form of Nicotinic Acid to Support Heart Health
4. Global Insulin Market Expected to Reach USD 32,346.7 Million in 2018, with China Alone Accounting for 10.2%: Transparency Market Research
5. Without Magnesium, Vitamin D & Calcium Alone Will Not Prevent Bone Fractures
6. Dr. Prem Reddy Named Among Most Influential Physician Executives in Nation
7. Brain Research Foundation Announces Grant To Study Concussive Events Among Grade School Children
8. Imaging Healthcare Specialists Among the First in the Nation to Offer Imaging Diagnosis for Alzheimers Disease
9. Advanced Radiology Among the First in the U.S. to Offer New Alzheimers Disease Tracer
10. Social Norms, Life Changes and Increasing Pressures Contribute to Substance Abuse Among Adult Women
11. Frost & Sullivan: Miniaturization of Medical Devices Reduces Mortality Rates among Cardiac Dysrhythmia Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Research and Markets has announced the addition of the ... their offering. ... The ablation device global market is expected to grow at high ... Ablation is the minimally invasive therapeutic tissue excision procedure used ... removal, to the removal of abnormally conducting cardiac tissue in atrial ...
(Date:3/29/2017)... , March 29, 2017  Spiral Therapeutics, ... agreement with Bionure Farma, S.L. for the worldwide ... to BN119 in the field of otolaryngology for ... sales-based royalties. The agreement provides Spiral with ... with a differentiated product profile. Under the terms ...
(Date:3/29/2017)... 2017   Royal Philips (NYSE: PHG, ... and PathAI, a company that develops artificial intelligence ... to develop solutions that improve the precision and ... diseases. The partnership aims to build deep learning ... artificial intelligence to be applied to massive pathology ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... AngioGenesis Labs sold 300 bottles ... AngioGenesis Labs, makers of HeartBoost, BrainBest and BeautyBest, achieved these results while doing ... an over the counter heart healthy drink, can reduce Arterial Plaque, Lower Blood ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... growing as it continues developing an ANSI-approved, consensus-based American National Standard for ... plans to publish the first ANSI-approved GMP standard for dietary supplements this ...
(Date:3/29/2017)... ... March 29, 2017 , ... HealthCareMandA.com will host an ... 20, 2017, at 1:00 PM ET. A recording of the webinar will also be ... Series. , Home health and hospice companies are still popular targets for healthcare investors. ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... of Gastrointestinal Oncology™ (SOGO™), a specialized continuing medical education conference for clinicians who ... at Intercontinental Time Square, New York. , The program will be led ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Tuesday, March 28, ... American public to take the Diabetes Risk Test to find out if they are ... Angeles World Airports will light up the evening sky by programming the LAX pylons ...
Breaking Medicine News(10 mins):